First Pass

32 stories from 13 sources

Drugmakers chase scale as care systems absorb new strain

Day’s Recap

Supporting Articles

12:00 AMFinancial Times

The $400bn megadeal brewing in big pharma

Summary

AstraZeneca is in talks to acquire Bristol Myers Squibb in a deal valued at about $400bn. The combination would create the world's fourth-largest drugmaker by market value.

The talks signal that scale is again becoming a strategic priority in big pharma, as

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A merger would redraw the global pharma landscape and put pressure on rivals to respond with deals of their own.

Link to Story
3:10 PMStat News

Ebola kills 1,700 in eastern Congo as the fastest-growing outbreak surges

Summary

Ebola has killed more than 1,700 people in eastern Congo as the region confronts what is described as the fastest-growing outbreak of the disease.

The death toll and accelerating spread point to a response under severe strain in a

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A fast-growing Ebola outbreak in a fragile health system raises the risk of wider regional transmission and a more difficult international response.

Link to Story
7:47 AMAl Jazeera

DR Congo Ebola outbreak kills more than 1,700 as WHO accelerates trials

Summary

An Ebola outbreak in the Democratic Republic of the Congo has killed more than 1,700 people, with nearly 90 percent of reported cases concentrated in Ituri province. The WHO is accelerating clinical trials as the outbreak continues.

The concentration of cases in Ituri makes the province the decisive front in containing the

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The outbreak's scale and geographic concentration are putting emergency response capacity and experimental treatments under immediate pressure.

Link to Story
4:17 PMMarketWatch

Novo Nordisk stock is sliding again — and the Wegovy pill’s surprise miss is partly to blame

Summary

Novo Nordisk shares fell after the company reported disappointing results for its oral Wegovy candidate, even as it improved its outlook for the year.

The weaker-than-expected pill results deepen concerns about whether Novo Nordisk can extend Wegovy's growth beyond

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The results expose the tension between Novo Nordisk's stronger near-term guidance and doubts about its next major growth engine.

Link to Story
12:48 PMBloomberg Markets

Novo Underwhelms Investors With Soft Wegovy Pill Sales

Summary

Novo Nordisk raised its full-year forecasts for the second time this year, driven by stronger expected sales of its obesity and diabetes medicines. Investors nevertheless sold the stock because the increase fell short of market expectations.

The shift is from demand uncertainty to a higher bar for growth. Novo's flagship drugs

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Strong drug demand is no longer enough to satisfy investors who have priced in exceptional growth.

Link to Story
12:00 AMFinancial Times

‘Arrogance kills’: Novo chief injects risk-taking into Ozempic maker

Summary

Novo Nordisk's chief executive, Mike Doustdar, says the company is open to large acquisitions and expects some failures as it works to reduce its dependence on weight-loss drugs.

Novo is shifting from defending its obesity and diabetes franchise to building a broader pipeline,

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The strategy signals that Novo sees its weight-loss dominance as an asset to reinvest, not a sufficient long-term growth plan.

Link to Story
1:09 PMCNBC

Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

Summary

Pfizer exceeded expectations and raised the lower end of its full-year revenue outlook, supported by Eliquis and other medicines. It nevertheless reduced its expected revenue from Covid products to about $4 billion from roughly $5 billion previously.

Pfizer’s results show the company is replacing pandemic-era revenue with growth from its broader portfolio,

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Pfizer’s recovery now depends on non-Covid medicines carrying the business as pandemic revenues recede.

Link to Story

2 stories · 2 sources

4:30 AMStat News

STAT+: Kennedy and Oz call Medicaid cuts ‘myths.’ It’s more complicated than that

Summary

Robert F. Kennedy Jr. and Mehmet Oz say new policies do not cut Medicaid. State Medicaid directors, however, warn that the changes could cause many people to lose coverage through new eligibility and administrative requirements.

The dispute turns on the difference between reducing the program's budget or benefits and reducing

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The policy's real impact will be measured by who remains insured, not by how officials label the changes.

Link to Story
6:04 AMAl Jazeera

Palestinian patients return to Gaza as thousands still await evacuation

Summary

Palestinian patients who received treatment abroad have returned to Gaza and reunited with their families. Thousands of others remain waiting for medical evacuation, leaving access to essential care dependent on movement across an active conflict zone.

The return of treated patients does not resolve the broader evacuation bottleneck. Gaza’s health crisis

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Medical evacuation delays convert a shortage of care into a time-sensitive threat to life and recovery.

Link to Story
9:23 AMStat News

STAT+: Are AI scribes medical devices? U.K. regulator weighs in

Summary

The report examines whether AI scribes should be regulated as medical devices in the United Kingdom. It also covers the removal of key U.S. payment pathways for breakthrough devices.

Regulatory classification will determine the evidence, oversight, and liability requirements for AI scribes used in

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Rules on classification and payment will shape which clinical AI products reach providers and patients.

Link to Story
4:00 AMPYMNTS

Healthcare AI Rules Shift Risk From Regulators to Hospitals

Summary

The article examines how looser or less prescriptive healthcare AI rules could accelerate startup activity and hospital adoption. It argues that reducing regulatory oversight may transfer more responsibility for safety, compliance, and clinical performance to hospitals and clinicians.

The key shift is where accountability sits: fewer front-end regulatory checks leave healthcare providers to

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Faster AI adoption could come with greater patient and legal risk if hospitals lack the capacity to evaluate the tools they buy.

Link to Story
11:54 AMStat News

STAT+: Three biotechs with three news updates

Summary

Gilead won a legal case involving its HIV medicine, Eli Lilly moved to broaden access to retatrutide, and other biotech companies reported additional developments. The updates span intellectual property, drug availability, and pipeline expansion.

The developments reinforce three forces shaping biotech: patent protection, access to high-demand medicines, and competition

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Legal decisions and access plans are rapidly reshaping which biotech products can reach patients and generate durable returns.

Link to Story
9:11 AMStat News

STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more

Summary

Eli Lilly confirmed that more patients will be able to apply for early access to retatrutide, an unapproved obesity drug. The broader briefing also covers a Gilead court victory and other pharmaceutical developments.

Expanded access increases the number of people who may receive retatrutide before approval, while also

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The program tests how drugmakers can respond to intense demand for obesity treatments before approval.

Link to Story

Other Developments

A curated list of other prominent stories from this day.

9:06 PMBloomberg Markets

Goldman-Backed Biotech Attovia Raises $289 Million in US IPO

Summary

Attovia Therapeutics, an early-stage drug developer targeting immune system diseases, raised $289 million in a US initial public offering. The shares priced at the top of the marketed range.

Pricing at the top of the range signals strong investor demand for Attovia despite its

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The deal shows that public markets remain open to select biotech companies with promising disease targets, even before they generate revenue.

Link to Story
8:31 PMPropertymarkets News

Families With Sick Kids to Receive Free Accommodation During Urgent or Extended Hospital Stays

Summary

Sydney Children's Hospitals Foundation and Scape by the Living Company are launching a program that will provide free accommodation to families of seriously ill children during urgent or extended hospital stays. The initiative is designed to support families connected to New South Wales children's hospitals.

The program addresses a practical cost that can compound the stress of prolonged pediatric treatment,

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Free nearby housing can remove a major barrier to sustained family presence during critical pediatric treatment.

Link to Story
8:17 PMBloomberg Markets

Shionogi Eyes More US Plants, M&A Deals

Summary

Shionogi plans to add more manufacturing sites in the US over the next decade. Chief Executive Isao Teshirogi said the company is actively pursuing at least three deals.

Shionogi is moving from organic expansion toward a US-focused acquisition program. The targets could increase

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Shionogi’s pipeline of at least three deals signals a broader push to build US manufacturing scale through acquisitions.

Link to Story
5:00 PMThe New York Times

South Korea Wants to Raise Its Birthrate but Doesn’t Have Enough NICU Doctors

Summary

South Korea's effort to reverse one of the world's lowest fertility rates is colliding with a broader emergency-care breakdown. The shortage is especially severe among doctors who care for high-risk newborns in neonatal intensive care units.

The shortage exposes a core constraint on South Korea's population strategy: encouraging births does not

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

South Korea cannot address its demographic crisis through birth incentives alone while critical newborn-care capacity is eroding.

Link to Story
4:00 PMNPR Arts

A volunteer's unexpected advice changed how she faced cancer

Summary

After Annabelle Gurwitch received a stage 4 lung cancer diagnosis, a volunteer living with the same disease urged her to stop fixating on the future and return her attention to living in the present.

The exchange shows how peer support can address a dimension of cancer care that medical

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Peer programs can offer patients emotional guidance that complements clinical care, especially when illness makes the future impossible to predict.

Link to Story
1:04 PMStat News

STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans

Summary

A startup pursuing scalable, custom CRISPR treatments has abandoned its plans. Although the FDA has signaled flexibility for therapies modeled on the Baby KJ case, the regulatory standards remain difficult for a small company to meet.

Regulatory flexibility has not yet translated into a workable development path for small gene-editing companies.

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The setback shows that scientific feasibility does not guarantee a viable path to commercializing individualized gene therapies.

Link to Story
12:56 PMMarketWatch

It’s getting easier for terminally ill people to end their own lives. What to know as laws change.

Summary

Medical-aid-in-dying laws are expanding, giving more terminally ill people a legal path to end their lives under defined safeguards. Eligibility generally depends on meeting three conditions, including a qualifying terminal illness and the ability to make and carry out the decision.

As more jurisdictions change their laws, access will depend increasingly on where patients live and

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The policy shift is widening end-of-life options while creating uneven access and new legal and clinical obligations.

Link to Story
9:33 AMScienceDaily

Cancer-fighting chewing gum cuts HPV levels by up to 93%

Summary

An engineered chewing gum reduced oral HPV levels by as much as 93% and nearly eliminated two bacteria associated with head and neck cancer. It preserved beneficial oral bacteria in the reported testing.

The result points to a localized prevention strategy that could reduce cancer-related pathogens without broadly

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A low-cost, noninvasive treatment could expand prevention options for oral HPV and related cancers.

Link to Story
8:43 AMCNBC

Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Summary

Merck raised its revenue outlook as sales of newer medicines grew. It lowered its profit guidance because of a charge linked to its acquisition of Terns Pharmaceuticals.

Merck is trading near-term earnings pressure for expanded growth prospects through business development. The higher

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Merck’s update shows how pharmaceutical dealmaking can strengthen future growth while weakening current profit metrics.

Link to Story
8:30 AMStat News

Trans federal employees sue over revoked health coverage

Summary

Transgender federal employees are suing over the revocation of their health coverage. The available material also references expanded retatrutide access and the cost of the 2025 measles outbreak, but does not provide details about how those subjects relate to the lawsuit.

The case puts access to gender-affirming health benefits for federal workers before the courts, with

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The lawsuit could determine whether federal employees retain access to gender-affirming care through their workplace insurance.

Link to Story
8:05 AMStat News

STAT+: The latest orphan drug exemptions may not be warranted, analysis finds

Summary

A new analysis questions a federal provision that exempts orphan drugs from Medicare price negotiations. It finds that some recent exemptions may not meet the policy's intended justification.

The analysis challenges the breadth of a protection that can shield drugs from negotiated prices

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The exemptions could preserve higher drug prices while weakening one of Medicare's main cost-control tools.

Link to Story
5:00 AMThe City

City and Insurer to Pay $53 Million Over Retiree Copay Lawsuit

Summary

The Mamdani administration and a major insurer agreed to pay up to $53 million to reimburse retired city employees who said they were improperly charged $15 medical copays under a retiree health plan.

The settlement shifts the financial consequences of the disputed copays to the city and insurer,

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The payout offers relief to retirees while adding a substantial liability to the city's health-benefit system.

Link to Story
4:30 AMStat News

STAT+: As Trump administration pushes court-ordered mental health care, a new report raises questions

Summary

A new study of New York’s court-ordered treatment for people with serious mental illness adds evidence to the debate over involuntary care. Its findings raise questions about whether compelled treatment produces the benefits policymakers expect and how such programs affect patients’ rights.

The report comes as the administration promotes court-ordered care, making evidence from New York directly

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

Policies that expand involuntary care could affect civil liberties and public spending without clear evidence of better outcomes.

Link to Story
1:15 AMScienceDaily

A common sugar may help cancer cells break free and spread

Summary

Researchers found that ovarian cancer cells surviving chemotherapy may release fructose, prompting nearby tumor cells to loosen, escape, and spread. The findings raise possible links to diet and cholesterol-lowering drugs, but have not been confirmed in patients.

The key shift is from viewing fructose only as a fuel to considering it a

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The mechanism could reveal new ways to prevent metastatic relapse in ovarian cancer.

Link to Story
12:28 AMBloomberg Markets

Jefferies' Cui Cui on Wuxi Apptec's Earnings

Summary

Wuxi AppTec beat earnings expectations and raised its full-year guidance, prompting Jefferies' Asia healthcare research chief to maintain a positive outlook for the contract research and manufacturing group.

The guidance increase signals stronger near-term demand and execution than investors expected. That supports Wuxi

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

A stronger forecast reinforces the role of outsourced drug development and manufacturing while testing investor confidence in China's biotech infrastructure.

Link to Story
12:00 AMFinancial Times

Do natural GLP-1s work?

Summary

Food-based and other so-called natural alternatives to GLP-1 weight-loss drugs are attracting interest, but their effectiveness remains uncertain and generally lacks the clinical evidence behind prescription treatments.

The market is exploiting demand for cheaper or more accessible substitutes, but biological claims are

Unlock the full First Pass Analysis to get a better understanding of why this story matters

Why it matters

The debate will shape how consumers spend on weight-loss products as demand expands beyond prescription medicines.

Link to Story

Make it yours

Build Your First Pass.

Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!